Financial Performance - Operating revenue for Q1 2023 was CNY 19,549,204.28, representing a year-on-year increase of 10.41%[10] - The total revenue for the company reached 46,732,868, with a year-on-year growth of 54.38%[10] - The company reported a net profit of 1,369,000, reflecting a growth rate of 1.59%[10] - The net profit for Q1 2023 was a loss of ¥5,017,164.38, compared to a loss of ¥1,502,363.92 in Q1 2022, reflecting a deterioration in performance[37] - The total comprehensive income for Q1 2023 was -4,524,008.02, compared to -794,661.06 in Q1 2022, indicating a worsening financial position[41] Assets and Liabilities - Total assets as of March 31, 2023, were CNY 436,951,728.18, a decrease of 0.99% compared to the end of 2022[10] - The company's total assets decreased to ¥433,235,143.97 in Q1 2023 from ¥445,373,260.47 in Q1 2022, a decline of approximately 2.9%[35] - Total liabilities decreased to ¥140,486,801.34 in Q1 2023 from ¥160,250,909.82 in Q1 2022, a reduction of about 12.3%[35] - Total liabilities decreased to ¥137,460,304.70 from ¥149,269,302.09, a reduction of about 7.9%[31] - Current liabilities decreased to ¥107,862,339.15 from ¥120,966,395.31, reflecting a decrease of approximately 10.8%[30] Equity and Share Capital - The company issued additional shares, increasing total share capital to 85,847,126 shares by the end of the reporting period[17] - Shareholders' equity increased to ¥299,491,423.48 from ¥292,060,490.74, an increase of about 2.4%[31] - The company's equity increased to ¥292,748,342.63 in Q1 2023 from ¥285,122,350.65 in Q1 2022, showing a growth of approximately 2.3%[35] Cash Flow - Cash flow from operating activities improved by 43.97%, with a net cash outflow of CNY 10,410,561.45 compared to CNY 18,579,497.50 in the previous year[10] - Cash flow from operating activities for Q1 2023 was -10,410,561.45, an improvement from -18,579,497.50 in Q1 2022[42] - Total cash inflow from financing activities in Q1 2023 was 29,400,000.00, compared to 18,450,000.00 in Q1 2022, indicating a 59.5% increase[44] Research and Development - Research and development expenses increased by 94.44% in Q1 2023, primarily due to projects not reaching capitalization milestones[12] - Research and development expenses for Q1 2023 were ¥2,564,982.42, compared to ¥1,319,186.47 in Q1 2022, indicating an increase of about 94.3%[36] - Research and development expenses rose to 2,201,483.58 in Q1 2023, up from 1,319,046.47 in Q1 2022, marking a 66.67% increase[40] Inventory and Receivables - Accounts receivable decreased by 30.75% compared to the beginning of the period, reflecting improved collection efforts[11] - Inventory increased by 32.57% as the company ramped up production and stockpiled raw materials[11] - Accounts receivable decreased to ¥72,647,648.57 from ¥104,902,192.43, representing a significant drop of about 30.7%[29] - Inventory increased to ¥92,184,986.76 from ¥69,539,290.67, marking an increase of approximately 32.5%[29] Corporate Activities - The company has no ongoing litigation or arbitration matters reported during the period[22] - The company has fulfilled its commitments regarding previously disclosed matters in a timely manner[22] - The company has not engaged in any significant mergers or acquisitions during the reporting period[22] - The company has plans for market expansion and new product development in the upcoming quarters[23] - The company plans to focus on market expansion and new product development in the upcoming quarters[32]
辰光医疗(430300) - 2023 Q1 - 季度财报